Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Aurobindo Pharma Ltd

AUROPHARMA.NS ✓ COMPLIANT ☆ Track — members

NSE India · Healthcare · Pharmaceuticals ·

India Mid Cap Analyst: BUY

Last Close

$17.00

▼ -2.48%

Market Cap $9.78B · Vol 824.84K

Key Metrics

P/E Ratio

25.34

FWD: 19.23

Market Cap

$9.78B

Mid Cap

Div Yield

0.25%

Quarterly dividend

EPS Growth

+30.92%

YoY

RSI (14)

61.66

Momentum

Beta

0.91

vs Market

52W High

$17.63

3.58% below

52W Low

$10.65

47.16% above

Volume

824.84K

Avg 956.85K

P/B

2.00

Price-to-book

ROE

10.12%

Return on equity

Free Float

45.21%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Aurobindo Pharma Ltd (AUROPHARMA.NS) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does AUROPHARMA.NS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-2.17%

+4.46%

+7.36%

+41.59%

YTD

+37.12%

+49.70%

+62.17%

+113.07%

Financials & Valuation

TTM · Annual

Total Revenue	$3.60B
Net Income	$374.82M
Revenue Growth (YoY)	+16.30%
Gross Margin	50.57%
Operating Margin	15.31%
Net Profit Margin	10.41%
ROE	10.12%
ROA · ROIC	9.44% · 8.63%

P/E Ratio	25.34
Forward P/E (FY1)	19.23
PEG Ratio	24.04
P/S	2.25
P/B	2.00
P/FCF	31.46
EPS Growth	+30.92%
Outstanding Shares	575.38M

Technical Indicators

50-Day SMA	$16.21
200-Day SMA	$13.98
RSI (14)	61.66
Beta	0.91
52-Week High	$17.63
52-Week Low	$10.65

Volume Today	824.84K
Avg Daily Volume (30D)	956.85K
Relative Volume	0.86x
Volatility (10D)	30.30
Volatility (30D)	24.86
Free Float	45.21%

Analyst Consensus

BUY

Current Price $17.00

Mean Target $17.71

52W Low$10.65 52W High$17.63

Current

Target

$10.65 $17.63

Current Analyst target

+4.18% upside potential · 27 analysts

Identifiers

ExchangeNSE India

FIGIBBG001S6NCG4

ISININE406A01037

CountryIndia

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 3, 2026

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

LLY Eli Lilly and Co -2.39% JNJ Johnson & Johnson -0.66% ABBV Abbvie Inc -0.54% NVS Novartis AG -0.55% NOVN.S Novartis AG -1.05%

Company Profile

Aurobindo Pharma Limited is an India-based pharmaceutical company. The Company is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, branded pharmaceuticals, generic pharmaceuticals, and related services. Its key therapeutic segments include Central nervous systems (CNS), Antiretrovirals (ARVs), Cardiovascular (CVS), SSP - Orals and Sterile, Anti-infectives, Anti-diabetics and Cephalosporins - Orals. It is engaged in developing a range of oncology, non-oncology prescription formulation, and hormonal products. It is developing topical as well as transdermal products in the dermatology therapeutic segment. It is marketing its products globally in approximately 150 countries. Its subsidiaries include APL Healthcare Limited, Auronext Pharma Private Limited, Auro Peptides Limited, APL Pharma Thai Limited, Auro Pharma Inc, Aurobindo Pharma (Malta) Limited, APL Swift Services (Malta) Limited, Aurobindo Pharma Industria Farmaceutica Ltd, and others.